5 results on '"Artioli, Grazia"'
Number of results to display per page
Search Results
2. sj-pdf-2-tmj-10.1177_03008916221146820 – Supplemental material for Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society
- Author
-
Milani, Andrea, Tuninetti, Valentina, Pignata, Sandro, Lorusso, Domenica, Castaldo, Daniele, De Giorgi, Ugo, Savarese, Antonella, Biglia, Nicoletta, Scandurra, Giuseppa, Mangili, Giorgia, Di Maio, Massimo, Turinetto, Margherita, Bellero, Marco, Mammoliti, Serafina, Testa, Silvia, Scotto, Giulia, Purro, Andrea, Artioli, Grazia, and Valabrega, Giorgio
- Subjects
Medicine - Abstract
Supplemental material, sj-pdf-2-tmj-10.1177_03008916221146820 for Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society by Andrea Milani, Valentina Tuninetti, Sandro Pignata, Domenica Lorusso, Daniele Castaldo, Ugo De Giorgi, Antonella Savarese, Nicoletta Biglia, Giuseppa Scandurra, Giorgia Mangili, Massimo Di Maio, Margherita Turinetto, Marco Bellero, Serafina Mammoliti, Silvia Testa, Giulia Scotto, Andrea Purro, Grazia Artioli and Giorgio Valabrega in Tumori Journal
- Published
- 2023
- Full Text
- View/download PDF
3. sj-pdf-1-tmj-10.1177_03008916221146820 – Supplemental material for Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society
- Author
-
Milani, Andrea, Tuninetti, Valentina, Pignata, Sandro, Lorusso, Domenica, Castaldo, Daniele, De Giorgi, Ugo, Savarese, Antonella, Biglia, Nicoletta, Scandurra, Giuseppa, Mangili, Giorgia, Di Maio, Massimo, Turinetto, Margherita, Bellero, Marco, Mammoliti, Serafina, Testa, Silvia, Scotto, Giulia, Purro, Andrea, Artioli, Grazia, and Valabrega, Giorgio
- Subjects
Medicine - Abstract
Supplemental material, sj-pdf-1-tmj-10.1177_03008916221146820 for Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society by Andrea Milani, Valentina Tuninetti, Sandro Pignata, Domenica Lorusso, Daniele Castaldo, Ugo De Giorgi, Antonella Savarese, Nicoletta Biglia, Giuseppa Scandurra, Giorgia Mangili, Massimo Di Maio, Margherita Turinetto, Marco Bellero, Serafina Mammoliti, Silvia Testa, Giulia Scotto, Andrea Purro, Grazia Artioli and Giorgio Valabrega in Tumori Journal
- Published
- 2023
- Full Text
- View/download PDF
4. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
- Author
-
Patel, Vivek L, Busch, Evan L, Friebel, Tara M, Cronin, Angel, Leslie, Goska, McGuffog, Lesley, Adlard, Julian, Agata, Simona, Agnarsson, Bjarni A, Ahmed, Munaza, Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L, Arason, Adalgeir, Arnold, Norbert, Artioli, Grazia, Arver, Brita, Auber, Bernd, Azzollini, Jacopo, Balmaña, Judith, Barkardottir, Rosa B, Barnes, Daniel R, Barroso, Alicia, Barrowdale, Daniel, Belotti, Muriel, Benitez, Javier, Bertelsen, Birgitte, Blok, Marinus J, Bodrogi, Istvan, Bonadona, Valérie, Bonanni, Bernardo, Bondavalli, Davide, Boonen, Susanne E, Borde, Julika, Borg, Ake, Bradbury, Angela R, Brady, Angela, Brewer, Carole, Brunet, Joan, Buecher, Bruno, Buys, Saundra S, Cabezas-Camarero, Santiago, Caldés, Trinidad, Caliebe, Almuth, Caligo, Maria A, Calvello, Mariarosaria, Campbell, Ian G, Carnevali, Ileana, Carrasco, Estela, Chan, Tsun L, Chu, Annie TW, Chung, Wendy K, Claes, Kathleen BM, Collaborators, Gemo Study, Collaborators, Embrace, Cook, Jackie, Cortesi, Laura, Couch, Fergus J, Daly, Mary B, Damante, Giuseppe, Darder, Esther, Davidson, Rosemarie, De La Hoya, Miguel, Puppa, Lara Della, Dennis, Joe, Díez, Orland, Ding, Yuan Chun, Ditsch, Nina, Domchek, Susan M, Donaldson, Alan, Dworniczak, Bernd, Easton, Douglas F, Eccles, Diana M, Eeles, Rosalind A, Ehrencrona, Hans, Ejlertsen, Bent, Engel, Christoph, Evans, D Gareth, Faivre, Laurence, Faust, Ulrike, Feliubadaló, Lídia, Foretova, Lenka, Fostira, Florentia, Fountzilas, George, Frost, Debra, García-Barberán, Vanesa, Garre, Pilar, Gauthier-Villars, Marion, Géczi, Lajos, Gehrig, Andrea, Gerdes, Anne-Marie, Gesta, Paul, Giannini, Giuseppe, Glendon, Gord, Godwin, Andrew K, Goldgar, David E, Greene, Mark H, Gutierrez-Barrera, Angelica M, Hahnen, Eric, Hamann, Ute, Hauke, Jan, Herold, Natalie, Hogervorst, Frans BL, Honisch, Ellen, Hopper, John L, Hulick, Peter J, Investigators, KConFab, Investigators, Hebon, Izatt, Louise, Jager, Agnes, James, Paul, Janavicius, Ramunas, Jensen, Uffe Birk, Jensen, Thomas Dyrso, Johannsson, Oskar Th, John, Esther M, Joseph, Vijai, Kang, Eunyoung, Kast, Karin, Kiiski, Johanna I, Kim, Sung-Won, Kim, Zisun, Ko, Kwang-Pil, Konstantopoulou, Irene, Kramer, Gero, Krogh, Lotte, Kruse, Torben A, Kwong, Ava, Larsen, Mirjam, Lasset, Christine, Lautrup, Charlotte, Lazaro, Conxi, Lee, Jihyoun, Lee, Jong Won, Lee, Min Hyuk, Lemke, Johannes, Lesueur, Fabienne, Liljegren, Annelie, Lindblom, Annika, Llovet, Patricia, Lopez-Fernández, Adria, Lopez-Perolio, Irene, Lorca, Victor, Loud, Jennifer T, Ma, Edmond SK, Mai, Phuong L, Manoukian, Siranoush, Mari, Veronique, Martin, Lynn, Matricardi, Laura, Mebirouk, Noura, Medici, Veronica, Meijers-Heijboer, Hanne EJ, Meindl, Alfons, Mensenkamp, Arjen R, Miller, Clare, Gomes, Denise Molina, Montagna, Marco, Mooij, Thea M, Moserle, Lidia, Mouret-Fourme, Emmanuelle, Mulligan, Anna Marie, Nathanson, Katherine L, Navratilova, Marie, Nevanlinna, Heli, Niederacher, Dieter, Nielsen, Finn C Cilius, Nikitina-Zake, Liene, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I, Ong, Kai-Ren, Osorio, Ana, Ott, Claus-Eric, Palli, Domenico, Park, Sue K, Parsons, Michael T, Pedersen, Inge Sokilde, Peissel, Bernard, Peixoto, Ana, Pérez-Segura, Pedro, Peterlongo, Paolo, Petersen, Annabeth Høgh, Porteous, Mary E, Pujana, Miguel Angel, Radice, Paolo, Ramser, Juliane, Rantala, Johanna, Rashid, Muhammad U, Rhiem, Kerstin, Rizzolo, Piera, Robson, Mark E, Rookus, Matti A, Rossing, Caroline M, Ruddy, Kathryn J, Santos, Catarina, Saule, Claire, Scarpitta, Rosa, Schmutzler, Rita K, Schuster, Hélène, Senter, Leigha, Seynaeve, Caroline M, Shah, Payal D, Sharma, Priyanka, Shin, Vivian Y, Silvestri, Valentina, Simard, Jacques, Singer, Christian F, Skytte, Anne-Bine, Snape, Katie, Solano, Angela R, Soucy, Penny, Southey, Melissa C, Spurdle, Amanda B, Steele, Linda, Steinemann, Doris, Stoppa-Lyonnet, Dominique, Stradella, Agostina, Sunde, Lone, Sutter, Christian, Tan, Yen Y, Teixeira, Manuel R, Teo, Soo Hwang, Thomassen, Mads, Tibiletti, Maria Grazia, Tischkowitz, Marc, Tognazzo, Silvia, Toland, Amanda E, Tommasi, Stefania, Torres, Diana, Toss, Angela, Trainer, Alison H, Tung, Nadine, Van Asperen, Christi J, Van Der Baan, Frederieke H, Van Der Kolk, Lizet E, Van Der Luijt, Rob B, Van Hest, Liselotte P, Varesco, Liliana, Varon-Mateeva, Raymonda, Viel, Alessandra, Vierstraete, Jeroen, Villa, Roberta, Von Wachenfeldt, Anna, Wagner, Philipp, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weitzel, Jeffrey N, Wieme, Greet, Yadav, Siddhartha, Yannoukakos, Drakoulis, Yoon, Sook-Yee, Zanzottera, Cristina, Zorn, Kristin K, D'Amico, Anthony V, Freedman, Matthew L, Pomerantz, Mark M, Chenevix-Trench, Georgia, Antoniou, Antonis C, Neuhausen, Susan L, Ottini, Laura, Nielsen, Henriette Roed, and Rebbeck, Timothy R
- Subjects
Adult ,Aged, 80 and over ,BRCA2 Protein ,Male ,Heterozygote ,endocrine system diseases ,Adolescent ,BRCA1 Protein ,Prostatic Neoplasms ,Genomics ,Middle Aged ,Prognosis ,3. Good health ,Young Adult ,Risk Factors ,Mutation ,Humans ,Genetic Predisposition to Disease ,skin and connective tissue diseases ,Genetic Association Studies ,Aged - Abstract
Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 3' region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001-c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71-4.68; P = 0.00004) and elevated risk of Gleason 8+ prostate cancer (HR = 4.95; 95% CI, 2.12-11.54; P = 0.0002). No genotype-phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer. SIGNIFICANCE: Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific BRCA2 mutation inherited by the at-risk individual.
5. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
- Author
-
Francesco Perrone, Maria Ornella Nicoletto, Francesco Raspagliesi, Lucia Cannella, Giovanni Scambia, Enrico Breda, Sabrina Chiara Cecere, Giuseppa Maltese, Gennaro Daniele, Alessandra Baldoni, Irene Floriani, Simona Signoriello, Sandro Pignata, Germana Tognon, Nicoletta Colombo, Stefano Greggi, Giovanni Lo Re, Domenica Lorusso, Gabriella Ferrandina, Vanda Salutari, Alice Bergamini, G. Artioli, Maria Carmela Piccirillo, Daniele, Gennaro, Lorusso, Domenica, Scambia, Giovanni, Cecere, Sabrina C., Nicoletto, Maria Ornella, Breda, Enrico, Colombo, Nicoletta, Artioli, Grazia, Cannella, Lucia, Lo Re, Giovanni, Raspagliesi, Francesco, Maltese, Giuseppa, Salutari, Vanda, Ferrandina, Gabriella, Greggi, Stefano, Baldoni, Alessandra, Bergamini, Alice, Piccirillo, Maria Carmela, Tognon, Germana, Floriani, Irene, Signoriello, Simona, Perrone, Francesco, Pignata, Sandro, Daniele, G, Lorusso, D, Scambia, G, Cecere, S, Nicoletto, M, Breda, E, Colombo, N, Artioli, G, Cannella, L, Lo Re, G, Raspagliesi, F, Maltese, G, Salutari, V, Ferrandina, G, Greggi, S, Baldoni, A, Bergamini, A, Piccirillo, M, Tognon, G, Floriani, I, Signoriello, S, Perrone, F, and Pignata, S
- Subjects
medicine.medical_specialty ,Paclitaxel ,Bevacizumab ,medicine.medical_treatment ,Carcinoma, Ovarian Epithelial ,Carboplatin ,03 medical and health sciences ,0302 clinical medicine ,Ovarian cancer ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Neoplasms, Glandular and Epithelial ,030212 general & internal medicine ,Aged ,Ovarian Neoplasms ,Interval debulking ,Neoadjuvant ,Surgery ,Combined Modality Therapy ,Cytoreduction Surgical Procedures ,Feasibility Studies ,Female ,Middle Aged ,Oncology ,Obstetrics and Gynecology ,Chemotherapy ,Antineoplastic Combined Chemotherapy Protocol ,Cytoreduction Surgical Procedure ,business.industry ,Ovarian Neoplasm ,Glandular and Epithelial ,Surgical wound ,Combination chemotherapy ,Perioperative ,medicine.disease ,Debulking ,Feasibility Studie ,Regimen ,Settore MED/40 - GINECOLOGIA E OSTETRICIA ,030220 oncology & carcinogenesis ,business ,Human ,medicine.drug - Abstract
Background Few data are available on the outcome of surgery after a bevacizumab-containing regimen. The MITO 16A- MaNGO OV2A phase 4 trial evaluates the outcomes of first-line CPB in a clinical-practice-like setting. Here we present the results of the subgroup of patients undergoing IDS after neoadjuvant treatment or suboptimal primary surgery. Methods 400 chemonaive epithelial ovarian cancer patients, age≥18, ECOG PS 0–2 were eligible to receive C (AUC 5 d1, q21) plus P (175mg/m 2 d1, q21) and B (15mg/kg d1 q21) for 6cycles followed by B maintenance until cycle 22nd. Results 79 patients (20%) underwent IDS. Overall, 74 patients received at least one administration of B before IDS. Median age was 61.2, 70% of the patients had FIGO IIIC disease. The median number of cycles before IDS was 3 both for chemotherapy and bevacizumab respectively. A residual disease ≤1cm was achieved in 64 patients (86.5%). Four percent of the patients experienced fever and 4% required blood transfusion after surgery. Surgical wound infection and/or dehiscence, pelvic abscess, intestinal sub-occlusion and fistula were experienced by one patient each. Conclusions In the MITO16A-MaNGO OV2A phase 4 trial, combined chemotherapy and bevacizumab did not hamper IDS and the rate of perioperative complications was similar to what expected without bevacizumab. These data support the hypothesis that adding bevacizumab to first line chemotherapy for ovarian cancer might not be denied to patients for whom IDS is planned.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.